Travere Therapeutics Provides Corporate Update and 2021 Outlook
11 janv. 2021 07h00 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for...
Travere Therapeutics to Host Virtual R&D Day on Wednesday, December 9, 2020
01 déc. 2020 16h30 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that the Company will host a virtual R&D Day on Wednesday, December 9, 2020 at 12:00 p.m. ET to...
Travere Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
30 nov. 2020 16h05 HE
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating...
Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc.
16 nov. 2020 08h00 HE
|
Retrophin, Inc.
New name reflects dedication to patient-inspired mission of identifying, developing and delivering life-changing rare disease therapies Company’s shares to trade under new ticker symbol TVTX on...
Retrophin to Present at Upcoming Investor Conferences
11 nov. 2020 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming virtual investor conferences in November...
Retrophin Reports Third Quarter 2020 Financial Results
05 nov. 2020 16h01 HE
|
Retrophin, Inc.
Pivotal DUPLEX Study of sparsentan in FSGS nears completion of enrollment; topline proteinuria data expected 1Q21 Pivotal PROTECT Study achieved enrollment of 280th patient with IgAN to enable...
Retrophin to Report Third Quarter 2020 Financial Results
21 oct. 2020 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2020 financial results on Thursday, November 5, 2020 after the close of the...
Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined
09 oct. 2020 16h01 HE
|
Retrophin, Inc.
SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with focal...
Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
21 sept. 2020 08h00 HE
|
Retrophin, Inc.
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety...
Retrophin Reports Second Quarter 2020 Financial Results
30 juil. 2020 16h01 HE
|
Retrophin, Inc.
Enrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now anticipated in 2021 Net product sales increased...